Genentech Gives Chance for Cure to Women Suffering From Breast Cancer Thanks to Herceptin
Posted on: Wednesday, 26 October 2005, 06:00 CDT
Genentech (San Francisco, USA), biotechnology company, gives a chance for cure to women suffering from breast cancer thanks to its drug Herceptin. The results of several scientific studies that were published in 4Q 2005 prove that Herceptin lowers the risk of recurrence to 50% in combination with chemotherapy
. Herceptin has been used to treat developed stages of breast cancer for several years. However, the costs on the treatment are very high, coming to USD 48,000/y. In 3Q 2005 the overall demand for Herceptin grew by 70% year-on-year, i.e. by USD 215.1 mil.Source: Access Czech Republic Business Bulletin
Related Articles
- Why Axa Says 'Oui' to Herceptin in France, but Not Britain
- Genentech Says Herceptin Could Cure Breast Cancer
- Herceptin Proves a Wonder Drug for Breast Cancer
- Pivotal Herceptin Data in The New England Journal of Medicine Showed Significant Improvement in Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
- Three More Provinces Approve Costly Breast Cancer Drug Herceptin
- Two More Provinces Approve Costly Breast Cancer Drug Herceptin
- Sales of Genentech/Roche/Chugai's Herceptin for the Treatment of Breast Cancer Will Nearly Triple By 2009
- UT Study Finds Herceptin Helpful in Fight Against Breast Cancer
- Genentech: Herceptin Hope for Breast Cancer Sufferers
Rating: 3.1 / 5 (15 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds